Harari lab
We aim to understand T-cells dynamic and correlates of efficacy in cancer patients treated with experimental immunotherapies and to develop analytical tools and pipelines for applications in immune discovery and in the development of novel strategies of cellular therapies ...
Research projects
Please check back later to discover our ongoing projects.
Latest publications
TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs.
Genolet R, Bobisse S, Chiffelle J, (...), Speiser DE, Coukos G, Harari A
Cell reports methods – 2023 Apr 24
Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes.
Racle J, Guillaume P, Schmidt J, (...), Bassani-Sternberg M, Harari A, Gfeller D
Immunity – 2023 Mar 30
Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity.
Fritah H, Graciotti M, Lai-Lai Chiang C, (...), Gfeller D, Harari A, Kandalaft LE
iScience – 2023 Feb 27
Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy.
Mastelic-Gavillet B, Sarivalasis A, Lozano LE, (...), Romero P, Kandalaft LE, Viganó S
Frontiers in immunology – 2023 Feb 10
Improved predictions of antigen presentation and TCR recognition with MixMHCpred2.2 and PRIME2.0 reveal potent SARS-CoV-2 CD8(+) T-cell epitopes.
Gfeller D, Schmidt J, Croce G, (...), Cesbron J, Racle J, Harari A
Cell systems – 2022 Dec 23
Team
Alexandre Harari
PhD Group leader, Human integrated tumor immunology discovery engine (Hi-TIDe) -T cell discovery, Department of Oncology UNIL & CHUV, Ludwig Institute for Cancer Research Lausanne
alexandre.harari@chuv.chOther members
Selected Publications
Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers.
Kandalaft LE, Harari A
Cancers – 2021 Nov 19
Sensitive identification of neoantigens and cognate TCRs in human solid tumors.
Arnaud M, Chiffelle J, Genolet R, (...), Bobisse S, Coukos G, Harari A
Nature biotechnology – 2021 Nov 15
The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients.
Arnaud M, Bobisse S, Chiffelle J, Harari A
Frontiers in immunology – 2021 Jul 30
Unsupervised Analysis of Flow Cytometry Data in a Clinical Setting Captures Cell Diversity and Allows Population Discovery.
Baumgaertner P, Sankar M, Herrera F, (...), Xenarios I, Guex N, Harari A
Frontiers in immunology – 2021 Apr 30
Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer.
Tanyi JL, Chiang CL, Chiffelle J, (...), Coukos G, Harari A, Kandalaft LE
NPJ vaccines – 2021 Mar 15
T-cell repertoire analysis and metrics of diversity and clonality.
Chiffelle J, Genolet R, Perez MA, (...), Coukos G, Zoete V, Harari A
Current opinion in biotechnology – 2020 Sep 2
Structural dissimilarity from self drives neoepitope escape from immune tolerance.
Devlin JR, Alonso JA, Ayres CM, (...), Gfeller D, Harari A, Baker BM
Nature chemical biology – 2020 Aug 17
Antitumour dendritic cell vaccination in a priming and boosting approach.
Harari A, Graciotti M, Bassani-Sternberg M, Kandalaft LE
Nature reviews. Drug discovery – 2020 Aug 6
Biotechnologies to tackle the challenge of neoantigen identification.
Arnaud M, Duchamp M, Bobisse S, (...), Renaud P, Coukos G, Harari A
Current opinion in biotechnology – 2020 Jan 8
Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes.
Racle J, Michaux J, Rockinger GA, (...), Jandus C, Bassani-Sternberg M, Gfeller D
Nature biotechnology – 2019 Oct 14
Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells.
Mastelic-Gavillet B, Navarro Rodrigo B, Décombaz L, (...), Romero P, Harari A, Vigano S
Journal for immunotherapy of cancer – 2019 Oct 10
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.
Tanyi JL, Bobisse S, Ophir E, (...), Harari A, Coukos G, Kandalaft LE
Science translational medicine – 2018 Apr 11
Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.
Bobisse S, Genolet R, Roberti A, (...), Kandalaft LE, Coukos G, Harari A
Nature communications – 2018 Mar 15
Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease.
Harari A, Rozot V, Bellutti Enders F, (...), Hanekom WA, Bart PA, Pantaleo G
Nature medicine – 2011 Feb 20
Related news
Events
AGORA PRS | June 6th
Events
PhD Thesis Defense | June 2nd
Events
Ludwig Distinguished Lecture, Prof. Rienk Offringa | May 10th
Events
